Background Image

Latest News

Oxford BioTherapeutics enters into Commercial  License Agreement with Genmab

3 October 2022

Oxford BioTherapeutics enters into Commercial License Agreement with Genmab

• OBT licenses to Genmab the rights to a novel, pre-clinical first-in-class immuno-oncology (IO) antibody.

• Under its Commercial License Agreement with OBT, Genmab will obtain the exclusive right to develop and commercialize novel antibody therapeutics utilizing OBT’s novel, first-in-class IO antibody.

• OBT will receive an undisclosed upfront and potential milestone payments and royalty payments on net product sales under the agreement.

Oxford, UK and San Jose, California, 3 October 2022 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody drug conjugate (ADC)-based therapies, today announced that global oncology leader, Genmab has licensed a novel antibody related to one of OBT’s IO programs. The target was discovered using Oxford BioTherapeutics’ proprietary OGAP® drug discovery platform, which incorporates one of the world’s largest proteomic databases, integrating clinical, experimental and expression data.

Under the terms of the agreement, Genmab will be responsible for the future development and commercialization of any products incorporating this antibody. In addition to the upfront payment, OBT will receive additional development and regulatory milestone payments as well as royalties on any future product sales. This represents the first major license agreement for OBT’s IO programs to a world leader in the field of antibody-based oncology medicines.

“We are pleased to license one of our leading immuno-oncology assets to a world leading biotechnology company like Genmab, who have a wealth of internationally renowned expertise in the fields of antibody development and oncology,” said Christian Rohlff, PhD, Chief Executive Officer (CEO) of Oxford BioTherapeutics. “This licensing deal enables OBT to add further depth and momentum into its drug pipeline by having this innovative asset developed by a partner.”